BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 22460505)

  • 1. Thioridazine induces apoptosis by targeting the PI3K/Akt/mTOR pathway in cervical and endometrial cancer cells.
    Kang S; Dong SM; Kim BR; Park MS; Trink B; Byun HJ; Rho SB
    Apoptosis; 2012 Sep; 17(9):989-97. PubMed ID: 22460505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Down-Regulation of the Mammalian Target of Rapamycin (mTOR) Pathway Mediates the Effects of the Paeonol-Platinum(II) Complex in Human Thyroid Carcinoma Cells and Mouse SW1736 Tumor Xenografts.
    He L; Guo S; Zhu T; Chen C; Xu K
    Med Sci Monit; 2020 Jun; 26():e922561. PubMed ID: 32594094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer.
    Nawroth R; Stellwagen F; Schulz WA; Stoehr R; Hartmann A; Krause BJ; Gschwend JE; Retz M
    PLoS One; 2011; 6(11):e27509. PubMed ID: 22110663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.
    Gao N; Flynn DC; Zhang Z; Zhong XS; Walker V; Liu KJ; Shi X; Jiang BH
    Am J Physiol Cell Physiol; 2004 Aug; 287(2):C281-91. PubMed ID: 15028555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.
    Peponi E; Drakos E; Reyes G; Leventaki V; Rassidakis GZ; Medeiros LJ
    Am J Pathol; 2006 Dec; 169(6):2171-80. PubMed ID: 17148679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of targeting endometrial stromal sarcoma cells via histone deacetylase and PI3K/AKT/mTOR signaling.
    Quan P; Moinfar F; Kufferath I; Absenger M; Kueznik T; Denk H; Zatloukal K; Haybaeck J
    Anticancer Res; 2014 Jun; 34(6):2883-97. PubMed ID: 24922651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PRAS40 is an integral regulatory component of erythropoietin mTOR signaling and cytoprotection.
    Chong ZZ; Shang YC; Wang S; Maiese K
    PLoS One; 2012; 7(9):e45456. PubMed ID: 23029019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.
    De P; Sun Y; Carlson JH; Friedman LS; Leyland-Jones BR; Dey N
    Neoplasia; 2014 Jan; 16(1):43-72. PubMed ID: 24563619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-99b suppresses human cervical cancer cell activity by inhibiting the PI3K/AKT/mTOR signaling pathway.
    Li YJ; Wang Y; Wang YY
    J Cell Physiol; 2019 Jun; 234(6):9577-9591. PubMed ID: 30480801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mammalian target of rapamycin pathway inhibition enhances the effects of 5-aza-dC on suppressing cell proliferation in human gastric cancer cell lines.
    Sun D; Toan X; Zhang Y; Chen Y; Lu R; Wang X; Fang J
    Sci China C Life Sci; 2008 Jul; 51(7):640-7. PubMed ID: 18622747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells.
    Ikezoe T; Nishioka C; Bandobashi K; Yang Y; Kuwayama Y; Adachi Y; Takeuchi T; Koeffler HP; Taguchi H
    Leuk Res; 2007 May; 31(5):673-82. PubMed ID: 17007924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PDCD6 additively cooperates with anti-cancer drugs through activation of NF-κB pathways.
    Park SH; Lee JH; Lee GB; Byun HJ; Kim BR; Park CY; Kim HB; Rho SB
    Cell Signal; 2012 Mar; 24(3):726-33. PubMed ID: 22142513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 4′,6-dihydroxy-4-methoxyisoaurone inhibits the HIF-1α pathway through inhibition of Akt/mTOR/p70S6K/4E-BP1 phosphorylation.
    Mi C; Ma J; Shi H; Li J; Wang F; Lee JJ; Jin X
    J Pharmacol Sci; 2014; 125(2):193-201. PubMed ID: 25075425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual inhibition of phosphatidylinositol 3-kinase/Akt and mammalian target of rapamycin signaling in human nonsmall cell lung cancer cells by a dietary flavonoid fisetin.
    Khan N; Afaq F; Khusro FH; Mustafa Adhami V; Suh Y; Mukhtar H
    Int J Cancer; 2012 Apr; 130(7):1695-705. PubMed ID: 21618507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fucoxanthin prevents cell growth and induces apoptosis in endometrial cancer HEC-1A cells by the inhibition of the PI3K/Akt/mTOR pathway.
    Qu J; Sun Y; Yang L; Niu X; Li L
    J Biochem Mol Toxicol; 2022 Jun; 36(6):e23027. PubMed ID: 35266250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
    Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. L-threonine regulates G1/S phase transition of mouse embryonic stem cells via PI3K/Akt, MAPKs, and mTORC pathways.
    Ryu JM; Han HJ
    J Biol Chem; 2011 Jul; 286(27):23667-78. PubMed ID: 21550972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
    Shoji K; Oda K; Kashiyama T; Ikeda Y; Nakagawa S; Sone K; Miyamoto Y; Hiraike H; Tanikawa M; Miyasaka A; Koso T; Matsumoto Y; Wada-Hiraike O; Kawana K; Kuramoto H; McCormick F; Aburatani H; Yano T; Kozuma S; Taketani Y
    PLoS One; 2012; 7(5):e37431. PubMed ID: 22662154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. microRNA-383 suppresses the PI3K-AKT-MTOR signaling pathway to inhibit development of cervical cancer via down-regulating PARP2.
    Teng P; Jiao Y; Hao M; Tang X
    J Cell Biochem; 2018 Jul; 119(7):5243-5252. PubMed ID: 29236322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of rapamycin sensitivity in breast cancer cells.
    Noh WC; Mondesire WH; Peng J; Jian W; Zhang H; Dong J; Mills GB; Hung MC; Meric-Bernstam F
    Clin Cancer Res; 2004 Feb; 10(3):1013-23. PubMed ID: 14871980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.